Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels.

Autor:	Keller GA; Universidad de Buenos Aires, Facultad de Medicina, Departamento de Toxicología y Farmacología, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina; Emergency Department, Hospital General de Agudos Donación Francisco J. Santojanni, Buenos Aires, Argentina., Villa Etchegoyen C; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Centro de Asesoramiento Toxicológico Analítico (CENATOXA), Buenos Aires, Argentina., Fernandez N; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Centro de Asesoramiento Toxicológico Analítico (CENATOXA), Buenos Aires, Argentina., Olivera NM; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Centro de Asesoramiento Toxicológico Analítico (CENATOXA), Buenos Aires, Argentina., Quiroga PN; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Centro de Asesoramiento Toxicológico Analítico (CENATOXA), Buenos Aires, Argentina., Diez RA; Universidad de Buenos Aires, Facultad de Medicina, Departamento de Toxicología y Farmacología, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina., Di Girolamo G; Universidad de Buenos Aires, Facultad de Medicina, Departamento de Toxicología y Farmacología, Centro de Vigilancia y Seguridad de Medicamentos e Instituto de Investigaciones Cardiológicas 'Prof. Dr. Alberto C. Taquini', Buenos Aires, Argentina.
Jazyk:	angličtina
Zdroj:	Journal of opioid management [J Opioid Manag] 2018 Sep/Oct; Vol. 14 (5), pp. 335-344.
DOI:	10.5055/jom.2018.0466
Abstrakt:	Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting. Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Setting: General ward of a public hospital of metropolitan Buenos Aires. Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study. Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval. Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels. Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was >450 ms in only one patient (only with the Hodge correction). There were no cases of QTc > 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R > 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R > 0.40-0.64) and ΔQTc (R > 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc > 30 ms and one patient with ΔQTc > 60 ms. No patient presented arrhythmia during the study. Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu